IPAR

Publicly Available Assessment Report for a
Veterinary Medicinal Product

DrySeal

PRODUCT SUMMARY

EU Procedure number	IE/V/0885/001/DC
Name, strength and pharmaceutical form	DrySeal intramammary suspension
Active substances(s)	Bismuth subnitrate
Applicant	Elanco GmbH Heinz-Lohmann-Strasse 4 27472 Cuxhaven Germany
Legal basis of application	Hybrid application (Article 19(1)(b) of Regulation (EU) 2019/6)
Date of Authorisation	10/07/2024
Target species	Cattle (dairy cows at drying off)
Indication for use	Prevention of new intramammary infections throughout the dry period. In cows considered likely to be free of sub-clinical mastitis, the veterinary medicinal product can be used on its own in dry cow management and mastitis control.
ATCvet code	QG52X
Concerned Member States	AT, CZ, DE, HU, IT, PL, SK, UK(NI)
Withdrawn CMS during the decentralised procedure	FR

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in relevant articles of Regulation (EU) 2019/6. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland. The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and Quantitative Particulars

The product contains 2.6 g bismuth subnitrate and the excipients aluminium di tri stearate, silica colloidal anhydrous and paraffin liquid.
The container/closure system consists of a 4 g single dose low-density polyethylene intramammary syringe with a smooth, tapered hermetically sealed nozzle with a low-density polyethylene cap and plunger.
The choice of the formulation is justified.
The product is an established pharmaceutical form, and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
Process validation data for the manufacturing process has been presented in accordance with the relevant European guidelines.
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

C. Control of Starting Materials

The active substance bismuth subnitrate, heavy is an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification has been provided.
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on Intermediate Products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods has been provided.
Batch analytical data from the proposed production sites has been provided demonstrating compliance with the specification.

F. Stability

Stabiliy data on the active substance has been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.
Stability data on the finished product has been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

This application has been submitted in accordance with Article 19(1) of Regulation (EU) 2019/6 (hybrid veterinary medicinal product).
The reference product cited is Boviseal Dry cow intramammary suspension for cattle (VPA 10387/101/001, Zoetis Belgium S.A.) which was first authorised on 25th June 2002.
Warnings and precautions as listed on the product literature are similar to those of the reference product and are adequate to ensure safety of the product to users, consumers and the environment.

III.A Safety Testing

Pharmacological Studies

As this is a hybrid application according to Article 19 of Regulation (EU) 2019/6 and essential similarity to a reference VMP has been demonstrated, results of pharmacodynamic or pharmacokinetic tests are not required.

Toxicological Studies

As this is a hybrid application according to Article 19 of Regulation (EU) 2019/6 and essential similarity to a reference VMP has been demonstrated, results of toxicological tests are not required.

User Safety

A user safety assessment in compliance with the relevant guideline has not been provided.
Given the similarity in formulations and the fact that this product is intended to be administered by the same route of administration at the same dose and for the same indications for use in the same species as the reference product, the omission was accepted on this occasion. That is, no greater risk to the user is anticipated following use of the product than that which already exists for the reference intramammary product.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

Phase I

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration of bismuth subnitrate in soil ($PEC_{soil, initial}$ = 49.0 µg/kg) is less than 100 µg/kg.

Conclusion

Based on the data provided, the ERA can stop at Phase I. The product is not expected to pose an unacceptable risk for the environment when used according to the SPC.

III.B Residues Documentation

Residue Studies

No residue depletion studies were conducted. The product and the reference product are of the same qualitative and quantitative composition in terms of active substance. The excipients are also considered to be qualitatively the same. In addition, the candidate product is intended to be administered by the intramammary route of administration, at the same dose, and for the same indications for use in the same species as the reference product. Given that the active substance is included in Table 1 of the Annex to Commission Regulation (EU) No. 37/2010 as "No MRL required" for all food-producing species, and that the excipients are also allowed substances with "No MRL required" status, it was accepted that any minor quantitative differences in relation to excipients will not impact on the withdrawal periods and that residue depletion studies are not required.

MRLs

Bismuth subnitrate is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	Marker residue	Animal Species	MRL	Target tissues	Other provision
Bismuth subnitrate	Not applicable	All food-producing species	No MRL required	Not applicable	For oral use only
		Bovines	No MRL required	Not applicable	For intramammary use only

Withdrawal Periods

Based on the data provided, the following withdrawal periods are justified:
Meat and offal: Zero days.
Milk: Zero hours.

IV. CLINICAL ASSESSMENT

IV.A Pre-Clinical Studies

As this is a hybrid application according to Article 19 of Regulation (EU) 2019/6 and essential similarity to a reference product has been demonstrated, pre-clinical studies are not required.

The efficacy claims for this product are equivalent to those of the reference product.

Tolerance in the Target Species of Animals

No target animal tolerance studies in the target species were conducted.
The product literature accurately reflects the type and incidence of adverse effects which might be expected.

IV.B Clinical Trials

As this is a hybrid application according to Article 19 of Regulation (EU) 2019/6 and essential similarity to a reference product has been demonstrated, clinical studies are not required.
The efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available in the Union Product Database (UPD).
This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.
None.